睿知中国医院研究地图
候选清单

南宁广西医科大学

广西医科大学第一附属医院

First Affiliated Hospital of Guangxi Medical University

在本站收录的 53 种疾病中,这家医院列在其中 27 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

广西医科大学第一附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma54 篇牵头论文牵头 5 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma135 篇牵头论文
  4. 胃癌Stomach cancer46 篇牵头论文
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 脊索瘤Chordoma0 篇牵头论文
  7. 骨肉瘤Osteosarcoma40 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma3 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma3 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma11 篇牵头论文
  11. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis3 篇牵头论文
  12. β 地中海贫血Beta thalassaemia25 篇牵头论文牵头 1 项开放试验
  13. 血友病 AHaemophilia A2 篇牵头论文
  14. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder3 篇牵头论文
  15. 重症肌无力Myasthenia gravis5 篇牵头论文
  16. 烟雾病Moyamoya disease4 篇牵头论文
  17. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis11 篇牵头论文
  18. 大动脉炎Takayasu arteritis2 篇牵头论文
  19. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  20. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  21. 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
  22. 白塞病Behçet disease0 篇牵头论文
  23. IgA 肾病IgA nephropathy4 篇牵头论文
  24. 成骨不全症Osteogenesis imperfecta1 篇牵头论文
  25. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  26. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  27. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:视网膜母细胞瘤、胃肠道间质瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 54 篇,占 2.3%。

牵头论文
54
2021–2025 年
牵头试验
11
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 131320222023: 9920232024: 181820242025: 882025

南宁有 5 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
    分期
    III期
    开始
    2026-03
    登记号
    NCT07459296

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院南宁

  2. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

  3. 即将招募
    Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2026-09
    登记号
    NCT07303283

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:广西医科大学第一附属医院南宁

  4. 即将招募
    Impacted Tooth Management and Osteoradionecrosis Risk in NPC
    分期
    不分期
    开始
    2026-08
    登记号
    NCT07764887

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 6 家列出的医院为研究中心中山、南宁、柳州、桂林、梧州

  5. 即将招募
    Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2024-11
    登记号
    NCT06680115

    年龄 18 岁 至 未注明(登记的条件)

    牵头:广西医科大学第一附属医院南宁

  6. 正在招募
    IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
    分期
    III期
    开始
    2024-01
    登记号
    NCT05941741

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 2 家列出的医院为研究中心南宁、南昌、广州

  7. 正在招募
    Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2024-05
    登记号
    NCT06445088

    年龄未注明(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 4 家列出的医院为研究中心中山、南宁、广州、梧州、福州

  8. 正在招募
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    分期
    III期
    开始
    2022-04
    登记号
    NCT05340491

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

  9. 正在招募
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    分期
    III期
    开始
    2020-03
    登记号
    NCT03907826

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术影像与人工智能复发与转移
论文中的科室放疗科病理/检验科耳鼻喉/头颈外科影像/核医学科
牵头的论文54
  1. BHLHE40-mediated upregulation of CAV1 decreases the radiosensitivity of nasopharyngeal carcinoma.2025American journal of physiology. Cell physiology
  2. Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study.2025BMC cancer免费全文
  3. Clinical features and CTA imaging of radiation-induced carotid pseudoaneurysms in nasopharyngeal carcinoma.2025BMC medical imaging免费全文
  4. Baseline audiometric assessment of newly diagnosed nasopharyngeal carcinoma patients: a multicentre cross-sectional study.2025International journal of cancer
  5. Radiomics based on dual-energy CT for noninvasive prediction of cervical lymph node metastases in patients with nasopharyngeal carcinoma.2025Radiography (London, England : 1995)
  6. The potential value of IVIM MR for radiation-related hypothyroidism in nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  7. Effect of HSPA 8 on the biological function of NPC cells and its mechanism.2025Scientific reports免费全文
  8. Carboxylesterase 4A Inhibits the Malignant Biological Behavior of Nasopharyngeal Carcinoma via the PI3K/AKT Pathway.2025Technology in cancer research & treatment免费全文
  9. Oncogenic and immunological roles of RACGAP1 in pan-cancer and its potential value in nasopharyngeal carcinoma.2024Apoptosis : an international journal on programmed cell death
  10. Establishment of a visualized mouse orthotopic xenograft model of nasopharyngeal carcinoma.2024Cancer biology & therapy免费全文
  11. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  12. Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  13. Circulating tumor cells: a valuable indicator for locally advanced nasopharyngeal carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  14. Prediction of severe radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma using the combined systemic immune-inflammatory index and prognostic nutritional index.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  15. The prognostic implications of radiologic extranodal extension in the lymph nodes of patients with nasopharyngeal cancer.2024Future oncology (London, England)免费全文
  16. Prognostic value of sarcopenia in the patients with locally advanced nasopharyngeal carcinoma.2024Japanese journal of radiology
  17. New T staging recommendations for recurrent nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncology免费全文
  18. Study on carotid artery stenosis after radiotherapy for nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncology免费全文
  19. Effects of concurrent chemoradiotherapy with or without Endostar on the regression of retropharyngeal lymph node and prognosis of patients with locally advanced nasopharyngeal carcinoma: a retrospective study.2024Journal of cancer research and clinical oncology免费全文
  20. LncRNA HOTAIRM1 promotes radioresistance in nasopharyngeal carcinoma by modulating FTO acetylation-dependent alternative splicing of CD44.2024Neoplasia (New York, N.Y.)免费全文
  21. Quantitative parameter analysis of pretreatment dual-energy computed tomography in nasopharyngeal carcinoma cervical lymph node characteristics and prediction of radiotherapy sensitivity.2024Radiation oncology (London, England)免费全文
  22. Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  23. The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  24. Combined pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts survival and prognosis in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.2024Scientific reports免费全文
  25. Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: a randomized controlled trial.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  26. Risk factors and the nomogram model for malnutrition in patients with nasopharyngeal carcinoma.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  27. Taxonomy and anticancer potential of Streptomyces niphimycinicus sp. nov. against nasopharyngeal carcinoma cells.2023Applied microbiology and biotechnology
  28. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.2023BMC cancer免费全文
  29. Nomogram to Predict Long-Term Overall Survival and Cancer-Specific Survival of Radiotherapy Patients with Nasopharyngeal Carcinoma.2023BioMed research international免费全文
  30. Scheduling radiotherapy for patients with nasopharyngeal carcinoma in the corresponding time window can reduce radiation-induced oral mucositis: A randomized, prospective study.2023Cancer medicineRCT免费全文
  31. WDHD1 is over-expressed in nasopharyngeal carcinoma and may control the expression of ITGAV.2023FEBS open bio免费全文
  32. Exploring the expression of SNHG1 and its effect on the PI3K-AKT axis in nasopharyngeal cancer.2023Neoplasma
  33. Quality evaluation index development for nutritional management in patients with nasopharyngeal carcinoma during peri-radiotherapy.2023Nutrition (Burbank, Los Angeles County, Calif.)
  34. The application of the PDCA cycle in the nutritional management of patients with nasopharyngeal carcinoma.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  35. Performance of Pretreatment MRI-Based Radiomics in Recombinant Human Endostatin Plus Concurrent Chemoradiotherapy Response Prediction in Nasopharyngeal Carcinoma: A Retrospective Study.2023Technology in cancer research & treatment免费全文
  36. Analysis of the risk of death and clinical management for nasal or nasopharyngeal bleeding occurring after radiotherapy for nasopharyngeal carcinoma.2022Auris, nasus, larynx
  37. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.2022BMC cancer免费全文
  38. Clinical value and potential mechanisms of BUB1B up-regulation in nasopharyngeal carcinoma.2022BMC medical genomics免费全文
  39. Development and validation of an MRI-based radiomic model for predicting overall survival in nasopharyngeal carcinoma patients with local residual tumors after intensity-modulated radiotherapy.2022BMC medical imaging免费全文
  40. Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.2022CancerRCT
  41. Nomogram Based on Clinical and Radiomics Data for Predicting Radiation-induced Temporal Lobe Injury in Patients with Non-metastatic Stage T4 Nasopharyngeal Carcinoma.2022Clinical oncology (Royal College of Radiologists (Great Britain))
  42. Potential Molecular Mechanism of Upregulated Aryl Hydrocarbon Receptor Nuclear Translocator 2 in Nasopharyngeal Carcinoma.2022Computational and mathematical methods in medicine免费全文
  43. Predicting Nomogram for Severe Oral Mucositis in Patients with Nasopharyngeal Carcinoma during Intensity-Modulated Radiation Therapy: A Retrospective Cohort Study.2022Current oncology (Toronto, Ont.)免费全文
  44. Downregulation of MicroRNA-1 and Its Potential Molecular Mechanism in Nasopharyngeal Cancer: An Investigation Combined with In Silico and In-House Immunohistochemistry Validation.2022Disease markers免费全文
  45. Downregulated miR-150-5p in the Tissue of Nasopharyngeal Carcinoma.2022Genetics research免费全文
  46. FOXM1 regulates glycolysis in nasopharyngeal carcinoma cells through PDK1.2022Journal of cellular and molecular medicine免费全文
  47. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.2022Radiation oncology (London, England)免费全文
  48. Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  49. Long-term efficacy and adverse reactions of IMRT combined with Endostar versus IMRT combined with chemotherapy for locally advanced nasopharyngeal carcinoma: a retrospective study.2021Annals of palliative medicine
  50. Tubulin polymerization promoting protein family member 3 (TPPP3) overexpression inhibits cell proliferation and invasion in nasopharyngeal carcinoma.2021Bioengineered免费全文
  51. Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma.2021Bioengineered免费全文
  52. miRNAs derived from circulating small extracellular vesicles as diagnostic biomarkers for nasopharyngeal carcinoma.2021Cancer science免费全文
  53. Radiation Therapy-Induced Changes of the Nasopharyngeal Commensal Microbiome in Nasopharyngeal Carcinoma Patients.2021International journal of radiation oncology, biology, physics
  54. Prognostic nomogram to predict the distant metastasis after intensity-modulated radiation therapy for patients with nasopharyngeal carcinoma.2021Medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
  1. Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC正在招募NCT07459296牵头方III期2026-03 启动
  2. Impacted Tooth Management and Osteoradionecrosis Risk in NPC即将招募NCT07764887牵头方不分期2026-08 启动
  3. Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma即将招募NCT06680115牵头方II期2024-11 启动
  4. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy正在招募NCT05892354牵头方不分期2023-06 启动
  5. Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT02907710牵头方III期2016-10 启动
  6. Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma已完成NCT02237924牵头方II期2014-09 启动
  7. Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma即将招募NCT07303283牵头方(推断)II期2026-09 启动
  8. Hearing Impairment of Nasopharyngeal Carcinoma已完成NCT05330169牵头方(推断)2022-09 启动
  9. PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma进行中,不再招募NCT05340270牵头方(推断)II期2022-07 启动
  10. Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma已完成NCT04004871牵头方(推断)II期2019-03 启动
  11. A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT01479504牵头方(推断)III期2011-11 启动
  12. Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma正在招募NCT06445088研究中心2024-05 启动
  13. IC Plus Low-dose Radiation Plus Cadonilimab in LANPC正在招募NCT05941741研究中心III期2024-01 启动
  14. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial正在招募NCT05340491研究中心III期2022-04 启动
  15. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients正在招募NCT03907826研究中心III期2020-03 启动
  16. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma进行中,不再招募NCT06712888研究中心III期2025-02 启动
  17. Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma进行中,不再招募NCT05780372研究中心III期2023-08 启动
  18. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma进行中,不再招募NCT05979961研究中心III期2023-09 启动
  19. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images状态不明NCT05627310研究中心2022-11 启动
  20. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  21. Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis已暂停NCT02022293研究中心II期2017-01 启动
  22. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)56
  1. 1393P MiPEP133 promoting radiosensitivity of nasopharyngeal carcinoma via downregulation of ACL-mediated DNA break2025Annals of Oncology论文
  2. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncology论文
  3. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  4. Additional file 1 of Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study2025Figshare论文
  5. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncology论文
  6. Induction chemotherapy with or without toripalimab followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, open-label, randomized, controlled, phase 2 trial.2025Journal of Clinical Oncology会议摘要
  7. Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study2025Figshare补充材料
  8. The Impact of Air Cavity Correction on Optimization Convergence Error in Intensity-Modulated Radiation Therapy Planning for Nasopharyngeal Carcinoma2025ScienceDB数据集
  9. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  10. Acetyl-CoA acyltransferase 1 is a potential tumor suppressor gene associated with immune cell infiltration in nasopharyngeal carcinoma2024Research Square预印本
  11. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncology会议摘要
  12. Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.2024Journal of Clinical Oncology会议摘要
  13. Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.2024Journal of Clinical Oncology会议摘要
  14. Predicting the risk of sarcopenia in Nasopharyngeal Carcinoma patients: Development and assessment of a new predictive nomogram2024Research Square预印本
  15. Prognostic Analysis of Nonmetastatic Nasopharyngeal Carcinoma in Older Patients Undergoing Intensity‐Modulated Radiotherapy2024International Journal of Clinical Practice论文
  16. Additional file 1 of Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway2023Figshare数据集
  17. Additional file 3 of Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway2023Figshare数据集
  18. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  19. Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.2023Journal of Clinical Oncology会议摘要
  20. Efficacy and safety of immunonutrition in preventing oral mucositis during concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.2023Journal of Clinical Oncology会议摘要
  21. Exploring the Clinical Characteristics and Survival of Early-Onset and Late-Onset Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  22. Icariside II targets in vitro MAPK and PI3K/Akt signaling in human nasopharyngeal carcinoma cells to induce apoptotic death and suppress proliferation2023Research Square预印本
  23. Impact of radiotherapy for nasopharyngeal carcinoma on carotid stenosis risk: a meta-analysis2023Figshare数据集
  24. Perspective Chapter: Modulation of Latent to Lytic Cycle Infection Switch and Its Implication in EBV Mediated Tumorigenicity2023IntechOpen eBooks书籍章节
  25. Potential Predictive Value of Intravoxel Incoherent Motion Magnetic Resonance for Xerostomia of Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  26. Surgical treatment of oligometastatic nasopharyngeal carcinoma2023Clinical Surgical Oncology论文
  27. The Feasibility of Level Ib Sparing Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma Patients with High-Risk Factors: Based on International Guideline2023International Journal of Radiation Oncology*Biology*Physics论文
  28. WITHDRAWN: Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: A randomized controlled trial2023Research Square预印本
  29. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  30. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  31. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figshare综述
  32. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  33. Additional file 2 of Development and validation of an MRI-based radiomic model for predicting overall survival in nasopharyngeal carcinoma patients with local residual tumors after intensity-modulated radiotherapy2022Figshare数据集
  34. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figshare数据集
  35. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  36. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  37. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  38. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  39. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  40. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  41. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  42. Analysis of hnRNP K Expression and Relevance for Clinical Outcomes in Hepatocellular carcinoma2022Research Square预印本
  43. Establishment of a visualized mouse orthotopic model of nasopharyngeal carcinoma.2022Journal of Clinical Oncology会议摘要
  44. Factors influencing out of pocket ratio to CPS among NPC patients in Guangxi: 2014-20202022IEEE International Conference on High Performance Computing and Communications; IEEE International Conference on Smart City; IEEE International Conference on Data Science and Systems (HPCC/SmartCity/DSS)会议论文
  45. Myocardin immunohistochemistry index is associated with clinical prognosis in nasopharyngeal carcinoma: a clinical practice-based cohort study2022Tropical Journal of Pharmaceutical Research论文
  46. Recombinant human endostatin combined with intensity-modulated radiotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A phase II, randomized, multicenter clinical trial.2022Journal of Clinical Oncology会议摘要
  47. The performance of pretreatment MR-based radiomics in Recombinant human endostatin plus concurrent chemoradiotherapy response prediction in nasopharyngeal carcinoma: A primary study2022Research Square预印本
  48. Upregulation of ITGAV and the underlying mechanisms in nasopharyngeal carcinoma2022Electronic Journal of Biotechnology论文
  49. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文
  50. Cucurbitacin B as a Chinese Medicine Monomer Inhibits Cell Proliferation, Invasion, and Migration in Nasopharyngeal Carcinoma2021Journal of Nanomaterials论文
  51. Diagnosis and Therapy of Nasopharyngeal Carcinoma2021IntechOpen eBooks书籍章节
  52. Endostar combined with intensity-modulated radiotherapy in low-risk local advanced nasopharyngeal carcinoma: A phase II, randomized, multicentric clinical trial.2021Journal of Clinical Oncology会议摘要
  53. Genome-Scale CRISPR-Cas9 Knockout Screening in Nasopharyngeal Carcinoma for Radiosensitive and Radioresistant Genes2021International Journal of Radiation Oncology*Biology*Physics论文
  54. Is the Equivalent Uniform Dose Model Being Used Properly? Impact of Dose Distribution on Parameter and Predictive Ability2021International Journal of Radiation Oncology*Biology*Physics论文
  55. Maintenance intervention to improve survival in patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment: A prospective multicenter randomized controlled clinical study.2021Journal of Clinical Oncology会议摘要
  56. Potential Role of The Upregulation of The Zinc Finger Protein of The Cerebellum 2 In Nasopharyngeal Carcinoma2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 1120242025: 112025

南宁有 4 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因
论文中的科室肿瘤内科病理/检验科
牵头的论文4
  1. Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation.2025Cancer medicine免费全文
  2. Comprehensive analysis of clinical features, mRNA splicing, and immunological role of REEP5 in esophageal squamous cell carcinoma.2024Scientific reports免费全文
  3. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.2021BMC cancer免费全文
  4. Overexpression of cyclin-dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance.2021FEBS open bio免费全文
PubMed 以外找到的论文(未计入)12
  1. Research on the Expression and Mechanism of LRRC8D in Esophageal Squamous Cell Carcinoma2025Research Square预印本
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  6. Exosomal circRNA FNDC3B promotes the progression of esophageal squamous cell carcinoma by sponging miR-490-5p and regulating thioredoxin reductase 1 expression2022Figshare数据集
  7. Significance of Sarcopenia and the Neutrophil-to-Lymphocyte Ratio in Elderly Patients with Esophageal Squamous Cell Carcinoma2022Book Publisher International (a part of SCIENCEDOMAIN International)书籍章节
  8. The Clinical Significance of Forkhead Box M1 in Esophageal Squamous Cell Carcinoma Tissues: A Study Based on In-house Immunohistochemistry, RNA-sequencing, and Data Mining2022Research Square预印本
  9. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集
  10. Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway2021Figshare数据集
  11. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figshare数据集
  12. Overexpression of UBE2C in Esophageal Squamous Cell Carcinoma Tissues and Molecular Analysis2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 135 篇,占 0.9%。

牵头论文
135
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 191920212022: 232320222023: 252520232024: 181820242025: 46462025

南宁有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2026-04
    登记号
    NCT07478302

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心南宁、福州

  2. 正在招募
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07170345

    年龄 18 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州

  3. 即将招募
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    分期
    未注明
    开始
    2026-07
    登记号
    NCT07724951

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 6 家列出的医院为研究中心上海、南宁、哈尔滨、广州、青岛

  4. 即将招募
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    分期
    II期
    开始
    2025-12
    登记号
    NCT07350070

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院;另有 4 家列出的医院为研究中心南宁、武汉、济南、福州、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现手术与肝移植
论文中的科室普外/肝胆胰外科影像/核医学科病理/检验科肿瘤内科
牵头的论文135
  1. Incorporating new criteria can improve the ability of CEUS LI-RADS to differentiate HCC from non-HCC malignancies.2026Abdominal radiology (New York)
  2. NSUN3-Mediated ROS Accumulation Promotes Hepatocellular Carcinoma Proliferation and Activates PI3K/AKT Pathway.2026Biochemical genetics
  3. Time-dependent diffusion-weighted MRI discriminates hepatocellular carcinoma from intrahepatic cholangiocarcinoma: A prospective animal model study.2026Magnetic resonance imaging
  4. Time-dependent diffusion MRI combined with enhanced MRI and clinical indicators for preoperative prediction of CK19 expression status in hepatocellular carcinoma: a prospective study.2026Magnetic resonance imaging
  5. A Phototherapy Nanosensitizer-Unlocked Multihit Strategy to Inhibit Tumor Stemness and Potentiate Sorafenib Response in Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  6. Development of a model combining CEUS LI-RADS and clinical features for predicting glypican-3 expression in hepatocellular carcinoma.2025Abdominal radiology (New York)
  7. Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma.2025Abdominal radiology (New York)
  8. Radiomics-based Machine Learning for Predicting Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2025Academic radiology
  9. An analysis of the clinical significance of the TKI-resistant gene ZNF687 for hepatocellular carcinoma patients.2025Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  10. Predictive value of intra-hepatectomy ICGR15 of the remnant liver for post-hepatectomy liver failure in hemi-hepatectomy: a prospective study.2025BMC cancer免费全文
  11. Donafenib activates the p53 signaling pathway in hepatocellular carcinoma, induces ferroptosis, and enhances cell apoptosis.2025Clinical and experimental medicine免费全文
  12. Silencing NCAPD3 Inhibits Tumor Growth and Metastasis in Hepatocellular Carcinoma by Suppressing PI3K-AKT Signalling Pathway.2025Current medical science
  13. Novel biomarker in hepatocellular carcinoma: Stearoyl-CoA desaturase 1.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  14. HBV-induced N6 methyladenosine modification of PARP1 enhanced AFB1-related DNA damage and synergistically contribute to HCC.2025Ecotoxicology and environmental safety
  15. Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma.2025European journal of medical research免费全文
  16. A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.2025Frontiers in immunology免费全文
  17. Stereotactic body radiation therapy combined with cadonilimab and lenvatinib in the treatment of hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombus: a prospective, multicenter, single-arm, phase II clinical trial.2025Frontiers in immunology免费全文
  18. The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.2025Frontiers in immunology免费全文
  19. Potential regulatory mechanism of overexpression of phosphatidylinositol glycan anchor biosynthesis class U on the glycolytic pathway in hepatocellular carcinoma.2025Gene
  20. FAHD1-mediated pyruvate metabolism in hepatocellular carcinoma: Multi-omics and causal genetic evidence.2025HGG advances免费全文
  21. Structural characterization and functional role of SLC7A6 in GSSG transport and Ferroptosis regulation.2025International journal of biological macromolecules
  22. Serum Alpha-Fetoprotein-Tumor Size Ratio as a Prognostic Marker After Hepatic Resection for Primary Hepatocellular Carcinoma: Propensity Score Matched Retrospective Cohort Study.2025JMIR cancer免费全文
  23. Development and Validation of an Extra Spindle Pole Bodies-like 1-Based Diagnostic and Prognostic Model for Hepatitis B Virus-Related Hepatocellular Carcinoma: Retrospective Cohort Study.2025JMIR medical informatics免费全文
  24. Impact of pre-examination video education in Gd-EOB-DTPA-enhanced liver MRI: A comparative study.2025Journal of medical radiation sciences免费全文
  25. Hsa_circ_0016662 acts as a prognostic biomarker and promotes the progression of hepatocellular carcinoma via autophagy regulation.2025Journal of translational medicine免费全文
  26. Proteomic and metabolomic analysis of platelet related samples reveals energy metabolism disorders in hepatocellular carcinoma.2025Journal of translational medicine免费全文
  27. AP5Z1 affects hepatocellular carcinoma growth and autophagy by regulating PTEN ubiquitination and modulating the PI3K/Akt/mTOR pathway.2025Journal of translational medicine免费全文
  28. Integrating single-cell and bulk RNA sequencing data to characterize the heterogeneity of glycan-lipid metabolism polarization in hepatocellular carcinoma.2025Journal of translational medicine免费全文
  29. Spleen volume after stage-I associated liver partition and portal vein ligation for staged hepatectomy predicts future liver remnant.2025Langenbeck's archives of surgery免费全文
  30. MRI-Based Topology Deep Learning Model for Noninvasive Prediction of Microvascular Invasion and Assisting Prognostic Stratification in HCC.2025Liver international : official journal of the International Association for the Study of the Liver免费全文
  31. Transformer model based on Sonazoid contrast-enhanced ultrasound for microvascular invasion prediction in hepatocellular carcinoma.2025Medical physics
  32. Balancing Image Quality and Iodine Intake: Insights from CT Spectral Imaging of the Portal Vein.2025Medical science monitor : international medical journal of experimental and clinical research免费全文
  33. Deubiquitinase-associated mRNA signature model predicts prognosis and influences the immune microenvironment in patients with hepatocellular carcinoma: An observational study.2025Medicine免费全文
  34. Overexpression of PLK1 Molecule Following Incomplete Thermal Ablation Promotes the Proliferation and Invasion of Residual Hepatocellular Carcinoma.2025Molecular biotechnology
  35. Heterogeneity of tumor-associated neutrophils in hepatocellular carcinoma.2025Molecular immunology
  36. Nitidine chloride inhibits the progression of hepatocellular carcinoma by suppressing IGF2BP3 and modulates metabolic pathways in an m6A-dependent manner.2025Molecular medicine (Cambridge, Mass.)免费全文
  37. METTL3/IGF2BP2 stabilizes IQGAP3 via m6A modification to drive HCC metastasis through TGF-β/Smad signaling and EMT.2025Pathology, research and practice
  38. Exploring the level of metabolic reprogramming and the role of prognostic factor SF3A3 in hepatocellular carcinoma through integrated single-cell landscape analysis.2025PloS one免费全文
  39. Epigallocatechin Gallate Derivative Y6 Reverses Oxaliplatin Resistance in Hepatocellular Carcinoma via Targeting the MiR-338-3p/HIF-1α/TWIST Axis to Inhibit EMT.2025Recent patents on anti-cancer drug discovery
  40. EXOSC3 knockdown induces G1/S phase arrest to suppress hepatocellular carcinoma cell proliferation.2025Scientific reports免费全文
  41. Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells.2025Scientific reports免费全文
  42. Fatty acid-binding proteins as potential biomarkers for human cancer prognosis.2025Scientific reports免费全文
  43. Exploreing the potential mechanism of Aitongxiao formula inhibiting hepatocellular carcinoma in vitro and in vivo based on network Pharmacology.2025Scientific reports免费全文
  44. Cystathionine gamma-lyase as an inflammatory factor and its link with immune inflammation in hepatitis B virus-related liver disease.2025Scientific reports免费全文
  45. The LncRNA lnc-POTEM-4:14 promotes HCC progression by interacting with FOXK1.2025Scientific reports免费全文
  46. Comprehensive Pan-Cancer Analysis and Functional Studies Reveal SLC2A6 as a Ferroptosis Modulator in Hepatocellular carcinoma.2025Scientific reports免费全文
  47. Liver resection in stage 0-A HCC in segments 7/8: a propensity-matched analysis comparing open, laparoscopic, and robotic approach.2025Surgical endoscopy免费全文
  48. 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione from Averrhoa carambola L. roots: Suppressing hepatocellular carcinoma progression through ROS accumulation and p53 pathway-mediated apoptosis.2025Toxicology and applied pharmacology
  49. Diagnostic performance of serum origin recognition complex subunit 1 protein for hepatitis B virus-related hepatocellular carcinoma.2025World journal of gastroenterology免费全文
  50. Robotic versus open hepatectomy for large(≥ 5 cm) hepatocellular carcinoma: A large volume center, propensity score matched study.2025World journal of surgical oncology免费全文
  51. Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma.2024Abdominal radiology (New York)
  52. Role of CCR1/5/7 in hepatocellular carcinoma: a study on prognostic evaluation, molecular subtyping, and association with immune infiltration.2024Aging免费全文
  53. RBCK1 overexpression is associated with immune cell infiltration and poor prognosis in hepatocellular carcinoma.2024Aging免费全文
  54. Prediction of prognosis of patients with hepatocellular carcinoma based on immune-related score.2024Asian journal of surgery
  55. M2 tumor-associated macrophages and CXCL2 induce lipid remodeling in hepatocellular carcinoma cell lines.2024Biomedical chromatography : BMC
  56. Prognostic value of geriatric nutritional risk index and prognostic nutritional index in hepatocellular carcinoma.2024Clinical nutrition ESPEN
  57. Value of the Stretched Exponential and Fractional-order Model in Differentiating Hepatocellular from Intrahepatic Cholangiocarcinoma.2024Current medical imaging
  58. Potential Value of the Stretched Exponential and Fractional Order Calculus Model in Discriminating Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: An Animal Experiment of Orthotopic Xenograft Nude Mice.2024Current medical imaging
  59. Exploring the impact of insufficient thermal ablation on hepatocellular carcinoma: NDST2 overexpression mechanism and its role in facilitating growth and invasion of residual cancer cells.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  60. A Novel Prognostic Model of Hepatocellular Carcinoma per Two NAD+ Metabolic Synthesis-Associated Genes.2024International journal of molecular sciences免费全文
  61. The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.2024Journal of cancer research and therapeutics
  62. Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues.2024Journal of gastrointestinal and liver diseases : JGLD
  63. Letter to Dr. Wang Jian and his team about our paper "Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study" published on "La radiologi2024La Radiologia medica
  64. Identification and validation of ATP6V1G1-regulated phosphorylated proteins in hepatocellular carcinoma.2024PloS one免费全文
  65. Nomogram based on the neutrophil-to-lymphocyte ratio and MR diffusion quantitative parameters for predicting Ki67 expression in hepatocellular carcinoma from a prospective study.2024Scientific reports免费全文
  66. Analysis of clinicopathologic and imaging features of dual-phenotype hepatocellular carcinoma.2024Scientific reports免费全文
  67. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.2024Scientific reports免费全文
  68. CEUS LI-RADS in Combination With the Serum Biomarker-Based ASAP Model Improves the Diagnostic Performance of HCC in High-Risk Patients.2024Ultrasound in medicine & biology
  69. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.2023Abdominal radiology (New York)
  70. SART3, regulated by p53, is a biomarker for diagnosis, prognosis and immune infiltration in hepatocellular carcinoma.2023Aging免费全文
  71. Correlation Between Serum ESPL1 and Hepatitis B Virus-related Hepatocellular Carcinoma Histological Grade: A Chinese Single-center Case-control Study.2023Anticancer research
  72. Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC.2023BMC medical imaging免费全文
  73. Development and validation of a nomogram for survival prediction in hepatocellular carcinoma after partial hepatectomy.2023BMC surgery免费全文
  74. The investigation on the hypercoagulability of hepatocellular carcinoma-related cerebral infarction with thromboelastography.2023Brain and behavior免费全文
  75. Advances in SEMA3F regulation of clinically high-incidence cancers.2023Cancer biomarkers : section A of Disease markers免费全文
  76. Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues.2023Cancer biotherapy & radiopharmaceuticals
  77. Highly expressed carbohydrate sulfotransferase 11 correlates with unfavorable prognosis and immune evasion of hepatocellular carcinoma.2023Cancer medicine免费全文
  78. Nucleoporin 107 is a prognostic biomarker in hepatocellular carcinoma associated with immune infiltration.2023Cancer medicine免费全文
  79. A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin.2023Discovery medicine
  80. Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.2023Frontiers in immunology免费全文
  81. 4-Methoxydalbergione Elicits Anticancer Effects by Upregulation of GADD45G in Human Liver Cancer Cells.2023Journal of healthcare engineering免费全文
  82. Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma.2023Journal of medical virology
  83. Comparison of the Feasibility and Diagnostic Performance of ACR CEUS LI-RADS and a Modified CEUS LI-RADS for HCC in Examinations Using Sonazoid.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  84. Can Modifications of LR-M Criteria Improve the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS for Small Hepatic Lesions up to 3 cm?2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  85. Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study.2023La Radiologia medicaRCT免费全文
  86. Pre-operative MRI features predict early post-operative recurrence of hepatocellular carcinoma with different degrees of pathological differentiation.2023La Radiologia medica免费全文
  87. Prognostic value and potential molecular mechanism of ITGB superfamily members in hepatocellular carcinoma.2023Medicine免费全文
  88. High expression of ENPP2 is an independent predictor of poor prognosis in liver cancer.2023Medicine免费全文
  89. Nomogram to predict the prognosis of patients with AFP-negative hepatocellular carcinoma undergoing chemotherapy: A SEER based study.2023Medicine免费全文
  90. A radiomics model based on magnetic resonance imaging to predict cytokeratin 7/19 expression and liver fluke infection of hepatocellular carcinoma.2023Scientific reports免费全文
  91. Robust analysis of a novel PANoptosis-related prognostic gene signature model for hepatocellular carcinoma immune infiltration and therapeutic response.2023Scientific reports免费全文
  92. Outer dynein arm docking complex subunit 2 polymorphism rs7893462 modulates hepatocellular carcinoma susceptibility and can serve as an overall survival biomarker for hepatitis B virus-related hepatocellular carcinoma after hepatectomy: a c2023World journal of surgical oncology免费全文
  93. Identify GADD45G as a potential target of 4-methoxydalbergione in treatment of liver cancer: bioinformatics analysis and in vivo experiment.2023World journal of surgical oncology免费全文
  94. Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at RAF1.2022Abdominal radiology (New York)
  95. Diagnostic performance and interreader agreement of CEUS LI-RADS in ≤ 30 mm liver nodules with different experienced radiologists.2022Abdominal radiology (New York)
  96. Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy.2022Annals of hepatology
  97. The expression characteristics and clinical significance of ACP6, a potential target of nitidine chloride, in hepatocellular carcinoma.2022BMC cancer免费全文
  98. Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma.2022BMC gastroenterology免费全文
  99. Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma.2022BioMed research international免费全文
  100. Long non-coding RNA LINC01793 as a potential diagnostic biomarker of hepatitis B virus-related hepatocellular carcinoma.2022Clinical biochemistry
  101. Diagnostic value of long noncoding RNA LINC01485 in patients with colorectal cancer.2022Clinical biochemistry
  102. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.2022European journal of radiology
  103. PSMB5 overexpression is correlated with tumor proliferation and poor prognosis in hepatocellular carcinoma.2022FEBS open bio免费全文
  104. A cohesin-associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma.2022FEBS open bio免费全文
  105. Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.2022Frontiers in endocrinology免费全文
  106. A novel Peng's test in reducing bile leakage after partial hepatectomy for hepatocellular carcinoma: From an animal study to a clinical cohort Propensity score matching comparative study.2022International journal of surgery (London, England)
  107. UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis.2022Journal of experimental & clinical cancer research : CR免费全文
  108. EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma.2022Journal of hepatology
  109. Multimodal imaging in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus.2022Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  110. Construction of a 3-mRNA hypoxia prognostic model to evaluate immune microenvironment in hepatocellular carcinoma.2022Medicine免费全文
  111. Gene mining of immune microenvironment in hepatocellular carcinoma.2022Medicine免费全文
  112. Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma.2022Medicine免费全文
  113. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways.2022PeerJ免费全文
  114. Testis-specific protein Y-encoded 1 regulates androgen receptor expression through the MAPK/ERK pathway in male hepatocellular carcinoma.2022Saudi medical journal免费全文
  115. Radiomics and nomogram of magnetic resonance imaging for preoperative prediction of microvascular invasion in small hepatocellular carcinoma.2022World journal of gastroenterology免费全文
  116. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.2022World journal of surgical oncology免费全文
  117. Comparison of Conventional Gadoxetate Disodium-Enhanced MRI Features and Radiomics Signatures With Machine Learning for Diagnosing Microvascular Invasion.2021AJR. American journal of roentgenology
  118. Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt.2021Abdominal radiology (New York)
  119. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.2021BMC cancer免费全文
  120. Effect of timing of surgical resection of primary hepatocellular carcinoma on survival outcomes in elderly patients and prediction of clinical models.2021BMC gastroenterology免费全文
  121. Hypomethylation-driven overexpression of HJURP promotes progression of hepatocellular carcinoma and is associated with poor prognosis.2021Biochemical and biophysical research communications
  122. Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis.2021Bioengineered免费全文
  123. Clinical significance and molecular mechanism of angiotensin-converting enzyme 2 in hepatocellular carcinoma tissues.2021Bioengineered免费全文
  124. Integrated multi-omics analysis of the clinical relevance and potential regulatory mechanisms of splicing factors in hepatocellular carcinoma.2021Bioengineered免费全文
  125. Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma.2021Bioengineered免费全文
  126. Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma.2021Bioengineered免费全文
  127. Preoperative combi-elastography for the prediction of early recurrence after curative resection of hepatocellular carcinoma.2021Clinical imagingRCT
  128. DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features.2021Frontiers in immunology免费全文
  129. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.2021Journal of experimental & clinical cancer research : CR免费全文
  130. Hepatic Arterioportal Fistula Is Associated with Decreased Future Liver Remnant Regeneration after Stage-I ALPPS for Hepatocellular Carcinoma.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  131. Expression of Cell Division Cycle Protein 45 in Tissue Microarrays and the CDC45 Gene by Bioinformatics Analysis in Human Hepatocellular Carcinoma and Patient Outcomes.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  132. Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma.2021Medicine免费全文
  133. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis.2021Medicine免费全文
  134. Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis: A protocol for systematic review and meta-analysis.2021Medicine免费全文
  135. Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus状态不明NCT06040177牵头方I/II期2023-02 启动
  2. AI Multimodal Model for Liver Cancer Diagnosis and Prognosis进行中,不再招募NCT07658586牵头方(推断)2025-12 启动
  3. A Study of DC-CIK to Treat Hepatocellular Carcinoma状态不明NCT01821482牵头方(推断)II期2013-05 启动
  4. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study即将招募NCT07724951研究中心2026-07 启动
  5. A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma正在招募NCT07478302研究中心I期2026-04 启动
  6. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension即将招募NCT07350070研究中心II期2025-12 启动
  7. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion正在招募NCT07170345研究中心2025-09 启动
  8. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  9. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  10. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)已完成NCT04000737研究中心II期2020-01 启动
  11. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  12. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects已终止NCT03591965研究中心II期2018-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 46 篇,占 0.5%。

牵头论文
46
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 131320222023: 5520232024: 111120242025: 12122025

南宁有 2 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南宁、大连、成都、杭州、武汉、石家庄、福州、苏州、银川

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能营养与康复腹膜转移与晚期
论文中的科室病理/检验科影像/核医学科消化/肝病科肿瘤内科
牵头的论文46
  1. Development and Validation of an AI-Based Multimodal Model for Pathological Staging of Gastric Cancer Using CT and Endoscopic Images.2025Academic radiology
  2. Comprehensive multi-omics pan-cancer analysis revealed EGFLAM as a potential prognostic and immune infiltration-associated biomarker.2025BMC cancer免费全文
  3. Comparison of outcomes between surgery and non-surgery after conversion therapy for advanced gastric cancer with unresectable factors: a systematic review and meta-analysis.2025BMC gastroenterology免费全文
  4. Unveiling the heterogeneity and immunotherapy potency of tumor-associated neutrophils in the tumor microenvironment of gastric cancer.2025BMC gastroenterology免费全文
  5. Transcription Factor MYB Upregulates IQGAP3 to Mediate DNA Repair and Promote 5-FU Resistance in Gastric Cancer Cells.2025Drug development research
  6. Exploring NUP62's role in cancer progression, tumor immunity, and treatment response: insights from multi-omics analysis.2025Frontiers in immunology免费全文
  7. CLIC1 regulates cellular oxidative stress and gastric cancer progress by enhancing ACOX1 ubiquitination.2025International journal of biological macromolecules
  8. Exosome-derived Menin from cancer-associated fibroblasts promotes gastric cancer progression by activating the HSPA6/JNK/JunD pathway and inducing EMT.2025Journal of translational medicine免费全文
  9. The CLIC1-PKM2 axis orchestrates glycolytic metabolism to accelerate gastric cancer progression.2025Journal of translational medicine免费全文
  10. Body Composition Decrease and Impact on Clinical Outcome in Gastric Cancer Patients Undergoing Radical Gastrectomy After Neoadjuvant Treatment.2025Nutrition and cancer
  11. Integrating visceral protein ratios and mid-arm circumference predicts survival and malnutrition in gastric cancer.2025Scientific reports免费全文
  12. Prognostic significance of anthropometric measurements in gastric cancer: a multicenter cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  13. CLIC1-mediated autophagy confers resistance to DDP in gastric cancer.2024Anti-cancer drugs免费全文
  14. Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.2024Anti-cancer drugs
  15. A nomogram for predicting nutritional risk before gastric cancer surgery.2024Asia Pacific journal of clinical nutrition免费全文
  16. Development and validation of a Radiopathomics model based on CT scans and whole slide images for discriminating between Stage I-II and Stage III gastric cancer.2024BMC cancer免费全文
  17. Human blood metabolites and gastric cancer: a Mendelian randomization analysis.2024BMC gastroenterology免费全文
  18. Identification of CERS5 as a molecular biomarker in pan-cancer through multiple omics integrative analysis.2024Cellular signalling
  19. Predicting malnutrition in gastric cancer patients using computed tomography(CT) deep learning features and clinical data.2024Clinical nutrition (Edinburgh, Scotland)
  20. Anoikis-related genes as potential prognostic biomarkers in gastric cancer: A multilevel integrative analysis and predictive therapeutic value.2024IET systems biology免费全文
  21. Predictive value of prognostic nutritional index in patients undergoing gastrectomy for gastric cancer: A systematic review and meta-analysis.2024Medicine免费全文
  22. Prevalence and unfavorable outcome of frailty in older adults with gastric cancer: a systematic review and meta-analysis.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  23. Application of the quality of recovery-40 questionnaire to evaluate the effectiveness of enhanced recovery after surgery protocols in gastric cancer.2024Updates in surgery免费全文
  24. Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer.2023BMC cancer免费全文
  25. Elian granules alleviate precancerous lesions of gastric cancer in rats by suppressing M2-type polarization of tumor-associated macrophages through NF-κB signaling pathway.2023BMC complementary medicine and therapies免费全文
  26. Construction of an autophagy-related eleven long noncoding RNA signature to predict the outcomes, immune cell infiltration, and immunotherapy response in patients with gastric cancer.2023Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  27. Pan-cancer analysis of the prognostic significance and oncogenic role of GXYLT2.2023Medicine
  28. Feasibility of olfactomedin 4 as a molecular biomarker for early diagnosis of gastric neoplasia after intestinal metaplasia.2023Scandinavian journal of gastroenterology
  29. Comparison of clinical-computed tomography model with 2D and 3D radiomics models to predict occult peritoneal metastases in advanced gastric cancer.2022Abdominal radiology (New York)
  30. Radiomics in Addition to Computed Tomography-Based Body Composition Nomogram May Improve the Prediction of Postoperative Complications in Gastric Cancer Patients.2022Annals of nutrition & metabolism
  31. DEAD-box helicase 56 functions as an oncogene promote cell proliferation and invasion in gastric cancer via the FOXO1/p21 Cip1/c-Myc signaling pathway.2022Bioengineered免费全文
  32. Tumor-derived extracellular vesicles shuttle c-Myc to promote gastric cancer growth and metastasis via the KCNQ1OT1/miR-556-3p/CLIC1 axis.2022Cell death & disease免费全文
  33. Comment on Granieri et al. "Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials".2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  34. Association of polymorphisms in PIN1 with progression and susceptibility in gastric cancer.2022Future oncology (London, England)
  35. Circ_0008287 promotes immune escape of gastric cancer cells through impairing microRNA-548c-3p-dependent inhibition of CLIC1.2022International immunopharmacology
  36. ITGA5 Promotes Tumor Progression through the Activation of the FAK/AKT Signaling Pathway in Human Gastric Cancer.2022Oxidative medicine and cellular longevity免费全文
  37. Mechanism of Elian granules in the treatment of precancerous lesions of gastric cancer in rats through the MAPK signalling pathway based on network pharmacology.2022Pharmaceutical biology免费全文
  38. Construction of a novel signature and prediction of the immune landscape in gastric cancer based on necroptosis-related genes.2022Scientific reports免费全文
  39. Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer.2022The International journal of biological markers
  40. SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation.2022TrialsRCT免费全文
  41. The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials.2022Updates in surgery
  42. Diagnostic Values of the Prealbumin-to-Fibrinogen, Albumin-to-Fibrinogen, and Monocyte-to-Lymphocyte Ratios in Gastric Cancer.2021Annals of clinical and laboratory science
  43. α-Actinin1 promotes tumorigenesis and epithelial-mesenchymal transition of gastric cancer via the AKT/GSK3β/β-Catenin pathway.2021Bioengineered免费全文
  44. CLIC1 knockout inhibits invasion and migration of gastric cancer by upregulating AMOT-p130 expression.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  45. Integrated analysis identifies oxidative stress genes associated with progression and prognosis in gastric cancer.2021Scientific reports免费全文
  46. Effects of Laparoscopic Radical Gastrectomy on Peritoneal Micrometastases of Gastric Cancer.2021Surgical laparoscopy, endoscopy & percutaneous techniques
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

南宁有 1 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南宁有 1 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 40 篇,占 1.8%。

牵头论文
40
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 111120222023: 131320232024: 5520242025: 662025

南宁有 10 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文40
  1. GSH-responsive Pt-based nanomotor with improved doxorubicin delivery for synergistic osteosarcoma chemotherapy.2025Acta biomaterialia
  2. N-terminal histone acetyltransferase NAA40 modulates osteosarcoma progression by controlling AGR2 expression.2025Biochemical and biophysical research communications
  3. Hsa_circ_0002005 aggravates osteosarcoma by increasing cell proliferation, migration, and invasion.2025Gene
  4. NFATC3 enhances osteosarcoma progression by increasing PD-L1 and CXCL2 levels.2025Medical oncology (Northwood, London, England)
  5. Formononetin enhances cisplatin chemotherapy sensitivity in osteosarcoma by inducing ferroptosis and reconstructing the immune microenvironment.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Prognostic significance of T cells and NK cells in osteosarcoma: a dual-center retrospective study.2025World journal of surgical oncology
  7. Single-cell and spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma.2024BMC medicine
  8. A Case of Non-calcified Intrahepatic Primary Osteosarcoma: A Case Report and a Literature Review.2024Current medical imaging
  9. Development of a Risk Model and Genotyping Patterns Based on Disulfidptosis-Related lncRNAs to Predict Prognosis and Immune Landscape in Osteosarcoma.2024Frontiers in bioscience (Landmark edition)
  10. Development and validation of neutrophil extracellular traps-derived signature to predict the prognosis for osteosarcoma patients.2024International immunopharmacology
  11. Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing.2024Medical oncology (Northwood, London, England)
  12. Identification and verification of a BMPs-related gene signature for osteosarcoma prognosis prediction.2023BMC cancer
  13. Pan-Cancer analysis of TERT and Validation in Osteosarcoma Cell Lines.2023Biochemical and biophysical research communications
  14. Hsa_circ_0007031 promotes the proliferation and migration of osteosarcoma cells by sponging miR-196a-5p to regulate the HOXB6.2023Biochemical pharmacology
  15. FAM60A promotes osteosarcoma development and progression.2023Cancer medicine
  16. Interaction gene set between osteoclasts and regulatory CD4+ T cells can accurately predict the prognosis of patients with osteosarcoma.2023Cancer science
  17. Circ_0001060 Upregulates and Encourages Progression in Osteosarcoma.2023DNA and cell biology
  18. A new insight of immunosuppressive microenvironment in osteosarcoma lung metastasis.2023Experimental biology and medicine (Maywood, N.J.)
  19. Analysis of scRNA-seq and bulk RNA-seq demonstrates the effects of EVI2B or CD361 on CD8+ T cells in osteosarcoma.2023Experimental biology and medicine (Maywood, N.J.)
  20. A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes.2023Frontiers in immunology
  21. Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1.2023Molecular cancer
  22. Long non-coding RNA and circular RNA and coding RNA profiling of plasma exosomes of osteosarcoma by RNA seq.2023Scientific data
  23. Identification of osteosarcoma m6A-related prognostic biomarkers using artificial intelligence: RBM15.2023Scientific reports
  24. RhRu Alloy-Anchored MXene Nanozyme for Synergistic Osteosarcoma Therapy.2023Small (Weinheim an der Bergstrasse, Germany)
  25. Efficacy of Diffusion-Weighted Imaging in Neoadjuvant Chemotherapy for Osteosarcoma: A Systematic Review and Meta-Analysis.2022Academic radiology
  26. A new model of preoperative systemic inflammatory markers predicting overall survival of osteosarcoma: a multicenter retrospective study.2022BMC cancer
  27. Significance of the neutrophil-to-lymphocyte ratio in predicting the response to neoadjuvant chemotherapy in extremity osteosarcoma: a multicentre retrospective study.2022BMC cancer
  28. PLCE1 is a poor prognostic marker and may promote immune escape from osteosarcoma by the CD70-CD27 signaling pathway.2022Bosnian journal of basic medical sciences
  29. Identification of Candidate MicroRNA-mRNA Subnetwork for Predicting the Osteosarcoma Progression by Bioinformatics Analysis.2022Computational and mathematical methods in medicine
  30. Construction of a transcription factor-miRNA-mRNA interactive network elucidates underlying pathogenesis for osteosarcoma and validation by qRT-PCR.2022Medicine
  31. Prognostic value of preoperative P-CRP in patients with osteosarcoma: A retrospective study of 101 cases.2022Medicine
  32. Two novel predictive biomarkers for osteosarcoma and glycolysis pathways: A profiling study on HS2ST1 and SDC3.2022Medicine
  33. The regulatory mechanism of LncRNA-mediated ceRNA network in osteosarcoma.2022Scientific reports
  34. Novel prognostic biomarkers, METTL14 and YTHDF2, associated with RNA methylation in Ewing's sarcoma.2022Scientific reports
  35. Five hypoxia and immunity related genes as potential biomarkers for the prognosis of osteosarcoma.2022Scientific reports
  36. Glycolysis- and immune-related novel prognostic biomarkers of Ewing's sarcoma: glucuronic acid epimerase and triosephosphate isomerase 1.2021Aging
  37. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.2021Cell proliferation
  38. STAT3 and its targeting inhibitors in osteosarcoma.2021Cell proliferation
  39. CCT6A, a novel prognostic biomarker for Ewing sarcoma.2021Medicine
  40. TYROBP, TLR4 and ITGAM regulated macrophages polarization and immune checkpoints expression in osteosarcoma.2021Scientific reports
中文论文(未计入)1
  1. [Polyphyllin VII inhibits osteosarcoma xenograft growth in mice by inducing ferroptosis via upregulating SOHLH1].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University
早期论文(2016–2020 年)16
  1. Intraperitoneal extraosseous osteosarcoma: a case report and literatures review.2020BMC musculoskeletal disorders
  2. m6A-dependent up-regulation of DRG1 by METTL3 and ELAVL1 promotes growth, migration, and colony formation in osteosarcoma.2020Bioscience reports
  3. Berberine enhances the radiosensitivity of osteosarcoma by targeting Rad51 and epithelial-mesenchymal transition.2020Journal of cancer research and therapeutics
  4. URG4 mediates cell proliferation and cell cycle in osteosarcoma via GSK3β/β-catenin/cyclin D1 signaling pathway.2020Journal of orthopaedic surgery and research
  5. Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients.2020Medicine
  6. Impact of Hydrogel Elasticity and Adherence on Osteosarcoma Cells and Osteoblasts.2019Advanced healthcare materials
  7. Untangling the response of bone tumor cells and bone forming cells to matrix stiffness and adhesion ligand density by means of hydrogels.2019Biomaterials
  8. Differential expression and bioinformatics analysis of circRNA in osteosarcoma.2019Bioscience reports
  9. Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.2019Molecular medicine reports
  10. [Application of pasteurized tumor-bearing bone replantation for primary malignant bone tumor of extremities].2019Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  11. To Explore the Mechanism of the GRM4 Gene in Osteosarcoma by RNA Sequencing and Bioinformatics Approach.2018Medical science monitor basic research
  12. Acute lymphoblastic leukemia arising after treatment of Ewing sarcoma was misdiagnosed as bone marrow metastasis of Ewing sarcoma: A case report.2018Medicine
  13. Long non-coding RNA HOXA11-AS functions as a competing endogenous RNA to regulate ROCK1 expression by sponging miR-124-3p in osteosarcoma.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  14. Icarisid II inhibits the proliferation of human osteosarcoma cells by inducing apoptosis and cell cycle arrest.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  15. Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control.2016Scientific reports
  16. Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

南宁有 3 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 0020232024: 0020242025: 002025

南宁有 2 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.7%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 1120232024: 2220242025: 332025

南宁有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-02
    登记号
    NCT07258511

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安

  2. 正在招募
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    分期
    未注明
    开始
    2026-06
    登记号
    NCT07663253

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 9 家列出的医院为研究中心上海、北京、南宁、南通、广州、成都、昆明、武汉、西安、郑州

  3. 正在招募
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06083207

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、南京、南宁、天津、徐州、武汉、苏州、西安

  4. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  5. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层干细胞移植联合用药
论文中的科室病理/检验科影像/核医学科
牵头的论文11
  1. Active Epstein-Barr virus infection and its association with multiple myeloma: evidence from a meta-analytical perspective.2025Hematology (Amsterdam, Netherlands)
  2. Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma.2025Hematology (Amsterdam, Netherlands)
  3. Visual assessment and quantitative analysis of dual-energy CT virtual non-calcium in imaging diagnosis of multiple myeloma.2025Skeletal radiology
  4. Association between BCL2 interacting protein 3 like (BNIP3L) genetic polymorphisms and the risk of multiple myeloma in China.2024Hematology (Amsterdam, Netherlands)
  5. Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma.2024Medicine免费全文
  6. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.2023Hematology (Amsterdam, Netherlands)
  7. 5-Amino-4-Imidazolecarboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase Polymorphisms Affect the Susceptibility to Multiple Myeloma.2022Laboratory medicine
  8. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.2022Leukemia research
  9. Upregulation of ATIC in multiple myeloma tissues based on tissue microarray and gene microarrays.2021International journal of laboratory hematology
  10. Integrated analysis of hub gene expression in multiple myeloma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  11. Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients正在招募NCT07663253研究中心2026-06 启动
  2. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07258511研究中心III期2026-02 启动
  3. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  4. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma正在招募NCT06083207研究中心I/II期2024-07 启动
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  7. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  8. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

南宁有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题淋巴瘤及肿瘤相关噬血EB病毒与感染诱因治疗方案
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 25 篇,占 8.0%。

牵头论文
25
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 6620232024: 1120242025: 11112025

南宁有 6 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
    分期
    早期I期
    开始
    2023-02
    登记号
    NCT05762510

    年龄 5 岁 至 35 岁(登记的条件)

    牵头:广西医科大学第一附属医院南宁

  2. 正在招募
    A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
    分期
    I期
    开始
    2024-01
    登记号
    NCT06465550

    年龄 3 岁 至 35 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、南宁、广州

  3. 正在招募
    A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
    分期
    I期
    开始
    2024-12
    登记号
    NCT06772766

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心南宁、海口

  4. 正在招募
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
    分期
    II期
    开始
    2019-11
    登记号
    NCT04143724

    年龄 6 岁 至 17 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心南宁、广州、成都、深圳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科儿科病理/检验科
牵头的论文25
  1. WGCNA and LASSO regression-based selection and validation of microRNA biomarkers of β-thalassemia.2026Blood cells, molecules & diseases
  2. Whole-Brain Analysis of Increased Brain Iron in Patients with β-Thalassemia.2025Academic radiology
  3. Neuroimaging in the diagnosis and treatment of cerebral toxoplasmosis in children with severe β-thalassemia after allo-HSCT.2025Biomolecules & biomedicine
  4. Study on Large-Scale Brain Network Abnormalities in Patients With Beta-Thalassemia.2025Brain and behavior
  5. Echocardiographic Left Atrial Stiffness Index Predicts Myocardial Iron Overload in Pediatric β-Thalassemia.2025Echocardiography (Mount Kisco, N.Y.)
  6. Predictive value of hepcidin and HIF1α protein levels for iron deposition in β-thalassemia.2025European journal of pediatrics
  7. Risk factors of low bone mass in young patients with transfusion-dependent beta-thalassemia.2025Frontiers in endocrinology
  8. IGHG4: innovative diagnostic biomarkers for iron overload in β-thalassemia patients.2025Hematology (Amsterdam, Netherlands)
  9. KLF1 Knockdown Differentially Regulates γ-Globin Expression: Inhibition in K562 Cells but Reactivation in β-Thalassemia Major Erythrocytes with Erythropoiesis Disruption.2025Hemoglobin
  10. Research on iron regulatory erythroid factors in children with β-thalassemia.2025Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  11. Correlation study between magnetic resonance imaging-quantitated cardiac iron deposition and left ventricular function in patients with β-thalassemia major in China.2025Science progress
  12. White matter microstructure abnormalities in thalassemia patients using TBSS analysis based on DTI.2025Scientific reports
  13. Research on the clinical factors of cardiac iron deposition in children with beta-thalassemia major.2024European journal of pediatrics
  14. Long-term Effect of Hematopoietic Stem Cell Transplantation on the Quality of Life of Patients with β-thalassemia Major in Guangxi, China - A Cross-sectional Study.2023Current stem cell research & therapy
  15. Identification of two novel β-globin gene mutations HBB: exon3del, HBB: c.-81A>C.2023Hematology (Amsterdam, Netherlands)
  16. Molecular Basis and Hematologic Phenotype of Hemoglobin H Disease Combined with Two Rare β-Globin Mutations.2023Hemoglobin
  17. Integration of targeted sequencing and pseudo-tetraploid genotyping into clinically assisted decision support for β-thalassemia invasive prenatal diagnosis.2023PloS one
  18. Magnetic resonance imaging assessment of the changes of cardiac and hepatic iron load in thalassemia patients before and after hematopoietic stem cell transplantation.2023Scientific reports
  19. Echocardiographic evaluation of left atrial strain for predicting iron overload in pediatric patients with β-thalassemia with preserved ejection fraction.2023The international journal of cardiovascular imaging
  20. Health-related quality of life in pediatric patients with β-thalassemia major after hematopoietic stem cell transplantation.2022Bone marrow transplantation
  21. Analysis of circRNAs and circRNA-associated competing endogenous RNA networks in β-thalassemia.2022Scientific reports
  22. Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome.2021Bone marrow transplantation
  23. Quality of Life in Patients with β-thalassemia Major: Short-term and Long-term Effects After Haematopoietic Stem Cell Transplantation.2021Current stem cell research & therapy
  24. Spectrum of β-Thalassemia Mutations in Some Areas of Guangxi Zhuang Autonomous Region of Southern China: A Study on a Pediatric Population Aged 0-15 Years.2021Hemoglobin
  25. Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics.2021The Annals of pharmacotherapy
早期论文(2016–2020 年)16
  1. A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.2020British journal of haematology
  2. Hereditary spherocytosis overlooked for 7 years in a pediatric patient with β-thalassemia trait and novel compound heterozygous mutations of SPTA1 gene.2020Hematology (Amsterdam, Netherlands)
  3. Compound Heterozygosity for a Novel Mutation Codon 104 (-A) (HBB: c.313delA) and Codons 41/42 (-CTTT) (HBB: c.126_129delCTTT) Leading to β-Thalassemia Major in a Chinese Family.2020Hemoglobin
  4. A Novel Mutation at HBB: c.91delA (Codon 30, -A) Causing β-Thalassemia in a Chinese Family.2019Acta haematologica
  5. G-CSF-Mobilized Blood and Bone Marrow Grafts as the Source of Stem Cells for HLA-Identical Sibling Transplantation in Patients with Thalassemia Major.2019Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  6. Immune recovery after in vivo T-cell depletion myeloablative conditioning hematopoietic stem cell transplantation in severe beta-thalassemia children.2019European journal of haematology
  7. Construction and Analysis of a Long Non-Coding RNA (lncRNA)-Associated ceRNA Network in β-Thalassemia and Hereditary Persistence of Fetal Hemoglobin.2019Medical science monitor : international medical journal of experimental and clinical research
  8. BCL11A Down-Regulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells.2018Hemoglobin
  9. ARHGAP18 is a novel gene under positive natural selection that influences HbF levels in β-thalassaemia.2018Molecular genetics and genomics : MGG
  10. Alterations of anticoagulant proteins and soluble endothelial protein C receptor in thalassemia patients of Chinese origin.2018Thrombosis research
  11. [Clinical analysis of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in thalassemia major].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  12. SOX6 Downregulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells.2017BioMed research international
  13. A Novel Variant with Positive Natural Selection Influenced Hb A2 Levels in Chinese Individuals with β-Thalassemia.2017Hemoglobin
  14. Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated co-expression and ceRNA networks in β-thalassemia and hereditary persistence of fetal hemoglobin.2017Oncotarget
  15. The prevalence of thalassemia in mainland China: evidence from epidemiological surveys.2017Scientific reports
  16. Prevalence of diabetes mellitus in Chinese children with thalassaemia major.2017Tropical medicine & international health : TM & IH
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]正在招募NCT05762510牵头方早期I期2023-02 启动
  2. A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia状态不明NCT06678165牵头方早期I期2024-12 启动
  3. Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study已完成NCT04009525牵头方IV期2019-07 启动
  4. Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major状态不明NCT03171831牵头方IV期2017-04 启动
  5. Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism状态不明NCT03101423牵头方不分期2016-08 启动
  6. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major正在招募NCT06465550研究中心I期2024-01 启动
  7. A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia正在招募NCT06772766研究中心I期2024-12 启动
  8. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia正在招募NCT04143724研究中心II期2019-11 启动
  9. A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major即将招募NCT07489196研究中心II期2026-04 启动
  10. A Long-term Follow-up Study in Participants Who Received CS-101邀请入组NCT06685536研究中心2025-01 启动
  11. A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection邀请入组NCT06717932研究中心2025-05 启动
  12. A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major已完成NCT06291961研究中心I期2024-04 启动
  13. CS-101 in Patients With β-thalassemia邀请入组NCT06328764研究中心早期I期2024-03 启动
  14. A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia已完成NCT06024876研究中心早期I期2023-08 启动
  15. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia进行中,不再招募NCT05577312研究中心I/II期2022-11 启动
  16. Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major已完成NCT02342145研究中心IV期2015-04 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

南宁有 2 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
论文中的科室病理/检验科儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

南宁有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断影像孕期、儿童与老人
论文中的科室神经内科眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025

南宁有 1 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题抗体与诊断生物制剂与补体抑制剂常规免疫治疗
论文中的科室神经内科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

南宁有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流血管重建手术中风与出血
论文中的科室神经内科神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 11 篇,占 4.2%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 3320232024: 3320242025: 112025

南宁有 2 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文11
  1. Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti-NMDAR Encephalitis-Associated Seizures.2025CNS neuroscience & therapeutics
  2. Abnormal global and local connectivity in patients with anti-N-methyl-D-aspartate receptor encephalitis: A resting-state functional MRI study.2024Brain research
  3. Identifying the Anti-inflammatory Effects of Astragalus Polysaccharides in Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Network Pharmacology and Experimental Validation.2024Combinatorial chemistry & high throughput screening
  4. The P38MAPK Pathway Mediates the Destruction of the Blood-Brain Barrier in Anti-NMDAR Encephalitis Mice.2024Neurochemical research
  5. Abnormalities in modular connectivity of functional brain networks and cognitive changes in patients with anti -N-methyl-D-aspartate receptor encephalitis.2023Brain research
  6. Inhibiting PI3K/Akt-Signaling Pathway Improves Neurobehavior Changes in Anti-NMDAR Encephalitis Mice by Ameliorating Blood-Brain Barrier Disruption and Neuronal Damage.2023Cellular and molecular neurobiology
  7. The alterations of spontaneous neural activities and white matter microstructures in anti-N-methyl-D-aspartate receptor encephalitis: a resting-state fMRI and DTI study.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Correlation analysis between regional homogeneity and executive dysfunction in anti-N-methyl-D-aspartate receptor encephalitis patients.2022European journal of neurology
  9. Aberrant resting-state interhemispheric functional connectivity in patients with anti-N-methyl-D-aspartate receptor encephalitis.2022Neuroradiology
  10. The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity.2021Multiple sclerosis and related disorders
  11. Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor encephalitis: a retrospective, multicenter, self-controlled study.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
早期论文(2016–2020 年)3
  1. Cerebral functional activity and connectivity changes in anti-N-methyl-D-aspartate receptor encephalitis: A resting-state fMRI study.2020NeuroImage. Clinical
  2. Voxel-based analysis and multivariate pattern analysis of diffusion tensor imaging study in anti-NMDA receptor encephalitis.2020Neuroradiology
  3. Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.2016Journal of neurology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

南宁有 2 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文2
  1. Formation of Multiple Intracranial Aneurysms Caused by Takayasu Arteritis.2024Radiology
  2. The diagnostic value of FDG PET/CT in Takayasu arteritis.2022Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

南宁有 2 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. A Novel 5-Methylcytosine- and Immune-Related Prognostic Signature Is a Potential Marker of Idiopathic Pulmonary Fibrosis.2022Computational and mathematical methods in medicine
早期论文(2016–2020 年)1
  1. Expression of GR-α and HDAC2 in steroid-Sensitive and steroid-Insensitive interstitial lung disease.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南宁有 1 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

南宁有 2 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南宁有 1 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

南宁有 3 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科影像/核医学科儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

南宁有 2 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

南宁有 1 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、宝鸡、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

南宁有 1 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南宁有 2 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

广西医科大学第一附属医院

First Affiliated Hospital of Guangxi Medical University

南宁

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
first Affiliated Hospital of Guangxi Medical University; First Affiliated Hospital of Guangxi Medical; First Affiliated Hospital of Guangxi Medical University Nanning

提出更正下载数据